Related Experiment Videos
Hepatic Steatosis and Morbid Obesity
1Department Upper GI Surgery and TPN, Royal Prince Alfred Hospital, Sydney, Australia.
Obesity Surgery
|May 1, 1993
Summary
Morbidly obese patients undergoing bariatric surgery frequently exhibit hepatic steatosis (fatty liver). However, this study found no evidence of significant liver damage like hepatitis or cirrhosis in these patients.
Area of Science:
- Hepatology
- Bariatric Surgery
- Obesity Medicine
Background:
- Morbid obesity is a significant health concern.
- Bariatric surgery is a common treatment for morbid obesity.
- Liver steatosis is prevalent in obese individuals.
Purpose of the Study:
- To assess the prevalence and severity of hepatic steatosis in morbidly obese patients.
- To investigate potential correlations between steatosis and patient demographics or preoperative liver function.
- To determine the presence of advanced liver disease in this population.
Main Methods:
- Open wedge liver biopsy performed on 127 morbidly obese patients post-bariatric surgery.
- Histological grading of hepatic specimens for steatosis.
- Analysis of patient data including obesity degree, age, sex, and liver function tests.
Main Results:
- Hepatic steatosis was observed in 75% of patients; severe, diffuse steatosis in 20%.
- No cases of fatty hepatitis, portal fibrosis, or cirrhosis were detected.
- No significant correlation found between obesity degree, age, sex, or liver function tests and steatosis severity.
Conclusions:
- Hepatic steatosis is highly prevalent in morbidly obese patients undergoing bariatric surgery.
- Advanced liver disease is not evident in this cohort.
- Further research is needed to explore the etiology of fatty liver in obesity.